Sources
Loading...
Additional media
Loading...
DeepNewz, mobile.
People-sourced. AI-powered. Unbiased News.
Terray Therapeutics has successfully closed an oversubscribed $120 million Series B funding round. The Los Angeles-based biotech company aims to advance its generative AI pipeline of small molecule therapeutics to the clinic by 2026. CEO Jacob Berlin highlighted the company's development of its own hardware in microarray chips to fuel its AI ambitions. The funding will support Terray's efforts in combining AI and drug targeting at scale, in collaboration with Nvidia ($nvda).
I’m excited to announce the closing of Series B for @Terray_Tx , a company I believe will transform the future of medicine. By combining AI and drug targeting at scale with Nvidia, Terray is paving the way for groundbreaking advancements $nvda 🚀 https://t.co/e029XQ5CUY https://t.co/SDQKB2sR67
I’m excited to announce the closing of Series B for @Terray_Tx , a company I believe will transform the future of medicine. By combining AI and drug targeting at scale with Nvidia, Terray is paving the way for groundbreaking advancements $nvda 🚀🧬 https://t.co/OwpLVhX49u
Terray Therapeutics Closes Oversubscribed $120M Series B to Advance Its Generative AI Pipeline of Small Molecule Therapeutics to the Clinic https://t.co/qWmzZyPOGt https://t.co/4RGgfTVgWS
